Over the past six months, more drug makers have begun posting their policies for gaining greater access to experimental medicines, according to a new analysis. However, more than half of all pharmaceutical manufacturers have yet to take this step to improve disclosure.

Specifically, 47 percent of 98 drug makers have posted a compassionate use policy on their web sites, compared with 19 percent last October. However, 84 percent of the 25 companies with a market capitalization of greater than $10 billion posted policies. This was up from 52 percent last fall.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • “Drug makers must agree to make their medicines available”. Ed, at this point I believe that companies can still opt to post “no access” on their website, so that I don’t think this statement is entirely correct.

    • Hi Pharmvet1,
      Thanks for the note. What I meant is that, drug makers must make their medicines available for patients to have access. Sorry for any semantic confusion.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy